---
layout: default
title: Vismodegib
description: "Vismodegib çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚åˆæ­¥è­‰æ“šç­‰ç´š L4ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 192
evidence_level: L2
indication_count: 10
---

# Vismodegib

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L4</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Vismodegibï¼šå¾åŸºåº•ç´°èƒç™Œåˆ°è‘—è‰²æ€§ä¹¾çš®ç—‡

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Vismodegib å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Vismodegib åŸæœ¬ç”¨æ–¼æ²»ç™‚è½‰ç§»æ€§åŸºåº•ç´°èƒç™Œã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**è‘—è‰²æ€§ä¹¾çš®ç—‡ (Xeroderma Pigmentosum)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **5 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æ²»ç™‚è½‰ç§»æ€§åŸºåº•ç´°èƒç™Œï¼Œæˆ–ä¸é©åˆæ¥å—æ‰‹è¡“æˆ–æ”¾å°„ç·šæ²»ç™‚ä¹‹å±€éƒ¨æ™šæœŸåŸºåº•ç´°èƒç™Œæˆäººç—…æ‚£ã€‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | basal cell carcinomaã€medulloblastoma with extensive nodularityã€sebaceous adenocarcinomaã€sweat gland cancerã€xeroderma pigmentosumã€skin carcinomaã€annular epidermolytic ichthyosisã€epidermolysis bullosa simplex with mottled pigmentationã€prostate cancer/brain cancer susceptibilityã€Brenner tumor |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.91% |
| è­‰æ“šç­‰ç´š | L4 |
| å°ç£ä¸Šå¸‚ | âœ“ å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 2 å¼µ |
| å»ºè­°æ±ºç­– | Research Question |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. medulloblastoma with extensive nodularity</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>ç›®å‰ç¼ºä¹è©³ç´°çš„ä½œç”¨æ©Ÿè½‰è³‡æ–™ã€‚æ ¹æ“šå·²çŸ¥è³‡è¨Šï¼ŒVismodegib æ˜¯ Hedgehog ä¿¡è™Ÿé€šè·¯æŠ‘åˆ¶åŠ‘ï¼Œ</p>
<p>å…¶æˆåˆ†åœ¨åŸºåº•ç´°èƒç™Œä¸­çš„ç™‚æ•ˆå·²è¢«è­‰å¯¦ï¼Œæ©Ÿè½‰ä¸Šå¯èƒ½é©ç”¨æ–¼è‘—è‰²æ€§ä¹¾çš®ç—‡æ‚£è€…çš„åŸºåº•ç´°èƒç™Œã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. xeroderma pigmentosum</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ5 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36921168/" target="_blank">36921168</a></td><td>2023</td><td>Article</td><td>Revista paulista de pediatria </td><td>Xeroderma pigmentosum: case report.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35283513/" target="_blank">35283513</a></td><td>2021</td><td>Article</td><td>Indian journal of dermatology</td><td>Current Therapeutic Strategies of Xeroderma Pigmentosum.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28297142/" target="_blank">28297142</a></td><td>2017</td><td>Article</td><td>Pediatric dermatology</td><td>Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old Chinese Boy with Xe...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30178564/" target="_blank">30178564</a></td><td>2018</td><td>Article</td><td>Pediatric dermatology</td><td>Use of vismodegib for the treatment of multiple basal cell carcinomas in a patie...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33901791/" target="_blank">33901791</a></td><td>2021</td><td>Article</td><td>European journal of cancer (Ox</td><td>Combination of targeted therapy and immune checkpoint blocker in a patient with ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. annular epidermolytic ichthyosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.87%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. epidermolysis bullosa simplex with mottled pigmentation</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. prostate cancer/brain cancer susceptibility</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.85%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. Brenner tumor</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. cutaneous adenocystic carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. prostate leiomyoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. skin cancer</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.82%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ23 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03035188" target="_blank">NCT03035188</a></td><td>PHASE2</td><td>COMPLETED</td><td>40</td><td>A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patient...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01815840" target="_blank">NCT01815840</a></td><td>PHASE2</td><td>COMPLETED</td><td>229</td><td>A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02690948" target="_blank">NCT02690948</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>16</td><td>A Phase 1b Open Label Study of Pembrolizumab for Unresectable or Metastatic Basa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03878524" target="_blank">NCT03878524</a></td><td>PHASE1</td><td>TERMINATED</td><td>2</td><td>Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART)...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01108094" target="_blank">NCT01108094</a></td><td>PHASE2</td><td>COMPLETED</td><td>29</td><td>Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients With ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01631331" target="_blank">NCT01631331</a></td><td>EARLY_PHASE1</td><td>COMPLETED</td><td>15</td><td>A Pilot Study to Investigate the Off Label Use of Vismodegib as an Adjuvant to S...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01367665" target="_blank">NCT01367665</a></td><td>PHASE2</td><td>COMPLETED</td><td>1232</td><td>A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of V...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05463757" target="_blank">NCT05463757</a></td><td>N/A</td><td>RECRUITING</td><td>80</td><td>Registration of Oral Hedgehog Inhibitors Vismodegib and Sonidegib in the Treatme...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01700049" target="_blank">NCT01700049</a></td><td>PHASE2</td><td>COMPLETED</td><td>28</td><td>ML28485:Phase 2B Single-site,Open-label,Nonrandomized Study Evaluating Efficacy ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01543581" target="_blank">NCT01543581</a></td><td>PHASE2</td><td>COMPLETED</td><td>3</td><td>Placebo-controlled, Double Blind Study to Assess Efficacy and Safety of Oral Vis...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02956889" target="_blank">NCT02956889</a></td><td>PHASE2</td><td>TERMINATED</td><td>14</td><td>A Single Arm, Phase II, Multicenter Study To Assess The Efficacy And Safety Of V...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05651828" target="_blank">NCT05651828</a></td><td>EARLY_PHASE1</td><td>RECRUITING</td><td>34</td><td>Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02694224" target="_blank">NCT02694224</a></td><td>PHASE2</td><td>UNKNOWN</td><td>40</td><td>A Randomized Phase II Pilot Study to Evaluate Safety and Efficacy of the Additio...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05238831" target="_blank">NCT05238831</a></td><td>EARLY_PHASE1</td><td>WITHDRAWN</td><td>0</td><td>Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART)...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04591431" target="_blank">NCT04591431</a></td><td>PHASE2</td><td>UNKNOWN</td><td>400</td><td>The Rome Trial From Histology to Target: the Road to Personalize Target Therapy ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01835626" target="_blank">NCT01835626</a></td><td>PHASE2</td><td>COMPLETED</td><td>24</td><td>A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Local...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01071564" target="_blank">NCT01071564</a></td><td>PHASE1</td><td>TERMINATED</td><td>13</td><td>A Phase I Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC # 747691) Pl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00607724" target="_blank">NCT00607724</a></td><td>PHASE1</td><td>COMPLETED</td><td>68</td><td>An Open-Label, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02366312" target="_blank">NCT02366312</a></td><td>PHASE2</td><td>COMPLETED</td><td>2</td><td>A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02465060" target="_blank">NCT02465060</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>6452</td><td>Molecular Analysis for Therapy Choice (MATCH)</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06357988" target="_blank">NCT06357988</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>35</td><td>MATCH Treatment Subprotocol T: GDC-0449 (Vismodegib) in Patients With Tumors (Ex...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01898598" target="_blank">NCT01898598</a></td><td>PHASE2</td><td>TERMINATED</td><td>18</td><td>A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Eff...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02337517" target="_blank">NCT02337517</a></td><td>PHASE2</td><td>TERMINATED</td><td>6</td><td>Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graf...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37604067/" target="_blank">37604067</a></td><td>2023</td><td>Article</td><td>European journal of cancer (Ox</td><td>European consensus-based interdisciplinary guideline for diagnosis and treatment...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22670903/" target="_blank">22670903</a></td><td>2012</td><td>Article</td><td>The New England journal of med</td><td>Efficacy and safety of vismodegib in advanced basal-cell carcinoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31990414/" target="_blank">31990414</a></td><td>2020</td><td>Article</td><td>Journal of the European Academ</td><td>Sonidegib and vismodegib in the treatment of patients with locally advanced basa...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26950094/" target="_blank">26950094</a></td><td>2016</td><td>Article</td><td>Nature genetics</td><td>Genomic analysis identifies new drivers and progression pathways in skin basal c...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27436804/" target="_blank">27436804</a></td><td>2016</td><td>Article</td><td>Actas dermo-sifiliograficas</td><td>Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part II: Photod...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32759706/" target="_blank">32759706</a></td><td>2020</td><td>Article</td><td>International journal of molec</td><td>Basal Cell Carcinoma: A Comprehensive Review.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26833519/" target="_blank">26833519</a></td><td>2016</td><td>Article</td><td>Clinical medicine (London, Eng</td><td>Non-melanoma skin cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31288208/" target="_blank">31288208</a></td><td>2019</td><td>Article</td><td>European journal of cancer (Ox</td><td>Diagnosis and treatment of basal cell carcinoma: European consensus-based interd...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38067165/" target="_blank">38067165</a></td><td>2023</td><td>Article</td><td>Cells</td><td>Basosquamous Carcinoma: Comprehensive Clinical and Histopathological Aspects, No...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34000246/" target="_blank">34000246</a></td><td>2021</td><td>Article</td><td>The Lancet. Oncology</td><td>Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor the...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29331385/" target="_blank">29331385</a></td><td>2018</td><td>Article</td><td>Journal of the American Academ</td><td>Guidelines of care for the management of basal cell carcinoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31466584/" target="_blank">31466584</a></td><td>2019</td><td>Article</td><td>Dermatologic clinics</td><td>Nonsurgical Treatments for Nonmelanoma Skin Cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24756807/" target="_blank">24756807</a></td><td>2014</td><td>Article</td><td>Recent results in cancer resea</td><td>Vismodegib.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30477683/" target="_blank">30477683</a></td><td>2018</td><td>Article</td><td>Annales de dermatologie et de </td><td>[Not Available].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35687691/" target="_blank">35687691</a></td><td>2022</td><td>Article</td><td>Science advances</td><td>Single-cell analysis of human basal cell carcinoma reveals novel regulators of t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27436800/" target="_blank">27436800</a></td><td>2016</td><td>Article</td><td>Actas dermo-sifiliograficas</td><td>Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part I: Topical...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35697404/" target="_blank">35697404</a></td><td>2022</td><td>Article</td><td>Actas dermo-sifiliograficas</td><td>Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24857041/" target="_blank">24857041</a></td><td>2014</td><td>Article</td><td>Expert opinion on drug discove</td><td>Discovery and preclinical development of vismodegib.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26566923/" target="_blank">26566923</a></td><td>2016</td><td>Article</td><td>International journal of derma</td><td>Oral therapy for nonmelanoma skin cancer in patients with advanced disease and l...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30045105/" target="_blank">30045105</a></td><td>2019</td><td>Article</td><td>Dermatologic surgery : officia</td><td>Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma S...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. benign neoplasm of sweat gland</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.82%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026444è™Ÿ | æ„›ç¶­å¾·è† å›Š150æ¯«å…‹ | è† å›ŠåŠ‘ | æ²»ç™‚è½‰ç§»æ€§åŸºåº•ç´°èƒç™Œï¼Œæˆ–ä¸é©åˆæ¥å—æ‰‹è¡“æˆ–æ”¾å°„ç·šæ²»ç™‚ä¹‹å±€éƒ¨æ™šæœŸåŸºåº•ç´°èƒç™Œæˆäººç—…æ‚£ã€‚ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šClarithromycinï¼ˆä¸­åº¦ï¼‰ã€Famotidineã€Ranitidineã€Rabeprazoleã€Cimetidine ç­‰ï¼ˆè¼•åº¦ï¼‰ã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**è‘¡è„æŸš** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šCYP3A4 ä»£è¬è—¥ç‰©ï¼Œè‘¡è„æŸšå¯èƒ½å½±éŸ¿è¡€ä¸­æ¿ƒåº¦
- å»ºè­°ï¼šé¿å…è‘¡è„æŸš


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Musculoskeletal Diseases** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šMusculoskeletal adverse reactions, which may be accompanied by serum creatine kinase elevations have been reported with the use of drugs that inhibit ...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šResearch Question**

**ç†ç”±ï¼š**
ç›®å‰æœ‰ä¸€äº›æ–‡ç»æ”¯æŒ Vismodegib åœ¨è‘—è‰²æ€§ä¹¾çš®ç—‡æ‚£è€…ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œä½†ç¼ºä¹è‡¨åºŠè©¦é©—çš„ç›´æ¥è­‰æ“šã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é€²ä¸€æ­¥çš„è‡¨åºŠè©¦é©—ä¾†è©•ä¼°å…¶ç™‚æ•ˆå’Œå®‰å…¨æ€§
- è©³ç´°çš„è—¥ç‰©ä½œç”¨æ©Ÿè½‰è³‡æ–™ï¼ˆMOAï¼‰

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Cisatracurium]({{ "/drugs/cisatracurium/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Ropinirole]({{ "/drugs/ropinirole/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Tetryzoline]({{ "/drugs/tetryzoline/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Acebutolol]({{ "/drugs/acebutolol/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Ritonavir]({{ "/drugs/ritonavir/" | relative_url }}) - è­‰æ“šç­‰ç´š L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Vismodegibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/vismodegib/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_vismodegib,
  title = {Vismodegibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/vismodegib/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
